154 related articles for article (PubMed ID: 2850327)
21. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
22. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
24. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
[TBL] [Abstract][Full Text] [Related]
25. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.
Bjornsson TD; Schneider DE; Hecht AR
J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
27. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1988; 543():65-72. PubMed ID: 2847460
[TBL] [Abstract][Full Text] [Related]
29. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.
Mätzsch T; Bergqvist D; Hedner U; Ostergaard P
Thromb Haemost; 1987 Feb; 57(1):97-101. PubMed ID: 3590085
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
Alban S; Welzel D; Hemker HC
Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
[TBL] [Abstract][Full Text] [Related]
31. Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations.
Ceriello A; Marchi E; Palazzni E; Quatraro A; Giugliano D
Diabete Metab; 1990; 16(2):86-92. PubMed ID: 2196192
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology of low molecular weight heparins.
Harenberg J
Semin Thromb Hemost; 1990 Oct; 16 Suppl():12-8. PubMed ID: 1962899
[TBL] [Abstract][Full Text] [Related]
33. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological profile of reviparin-sodium.
Hoppensteadt D; Jeske W; Fareed J
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S11-6. PubMed ID: 8180323
[TBL] [Abstract][Full Text] [Related]
35. [Chronopharmacology of fractionated heparin (nadroparin) administrated by subcutaneous route at prophylactic doses in healthy volunteers].
Mismetti P; Perpoint B; Laporte-Simitsidis S; Tardy-Poncet B; Reynaud J; Cherrah Y; Ollagnier M; Queneau P; Decousus H
Therapie; 1992 Nov; 47(6):557-60. PubMed ID: 1338741
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of low molecular weight heparins.
Bara L; Samama M
Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
38. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
39. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
40. Biochemical studies on sulfated lactobionic acid amides.
Klauser RJ; Meinetsberger E; Raake W
Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
